About

Welcome to the Lupus Forum. The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

Lupus Forum content is free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Membership of the Lupus Forum is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

View our latest Therapy Essentials
Watch the cGAS Podcast!
Biomarkers Webinar On-demand
Watch the JAKi podcast
EULAR 2025 Resources
CAR-T webinar on-demand

NEW Monthly literature search podcasts – available now

Join Professors Ed Vital and Maria Dall’Era, and Doctor Guillermo J. Pons-Estel for an expert-led discussion focusing on the latest ACR 2025 SLE Guidelines. This podcast provides an overview of the latest treatment recommendations, as well as ungraded, consensus-based good practice statements that are applicable to children and adults with SLE.

Latest Updates

Publications ▼
All
Publication thumbnail: BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis

BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis

Publication thumbnail: Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies

Publication thumbnail: Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Publication thumbnail: Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria

Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria

Steering Committee